Higher risks without cardio benefits halt study of aleglitazar
The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal ...
Mar 31, 2014
0
0